共 50 条
- [43] Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer? Annals of Surgical Oncology, 2021, 28 : 3605 - 3615
- [48] Survival after maximum effort cytoreductive surgery and platinum-based chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma and primary peritoneal carcinomatosis: Experience of a Public University Hospital in Spain GACETA MEXICANA DE ONCOLOGIA, 2019, 18 (01): : 13 - 21
- [50] AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer-Overall survival (OS) results JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)